When Bristol-Myers Squibb's mighty immunotherapy drug, Opdivo, failed in a large lung cancer trial in August, investorswiped $22 billion from the company's market value in a single afternoon. But it wasn't because they think the drug doesn't work. Most suspect it was something slightly more complicated — and they'll get much-anticipated answers this...